UBM — Ulisse Biomed Spa Cashflow Statement
0.000.00%
- €18.36m
- €17.19m
- €0.77m
- 29
- 20
- 23
- 11
Annual cashflow statement for Ulisse Biomed Spa, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 0.222 | -0.604 | -1.31 | -2.47 | -5.94 |
Depreciation | |||||
Non-Cash Items | -0.095 | -0.131 | -0.154 | 0.015 | — |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.779 | 0.092 | 0.171 | 0.743 | -0.499 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.601 | -0.395 | -0.97 | -1.39 | -3.52 |
Capital Expenditures | -0.108 | -0.956 | -0.228 | -0.099 | -0.035 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.001 | -0.002 | 0 | 0 | -0.006 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.109 | -0.958 | -0.228 | -0.098 | -0.041 |
Financing Cash Flow Items | -0.021 | 0 | — | — | 2.26 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -0.023 | 6.3 | 0.002 | 0 | 2.23 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.733 | 4.95 | -1.2 | -1.48 | -1.28 |